Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2024 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on June 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on May 10, 2024, the Compensation Committee of its Board of Directors granted inducement...
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
May 09, 2024 16:30 ET
|
Travere Therapeutics, Inc.
Presentations highlight data supporting FILSPARI® (sparsentan) as a foundational therapy over historical RASi standard of care and in newly diagnosed patients with IgAN SAN DIEGO, May 09, 2024 ...
Travere Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: BofA...
Travere Therapeutics Reports First Quarter 2024 Financial Results
May 06, 2024 16:01 ET
|
Travere Therapeutics, Inc.
FDA grants Priority Review for sNDA to convert FILSPARI® (sparsentan) from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 ...
Travere Therapeutics to Report First Quarter 2024 Financial Results
April 29, 2024 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report first quarter 2024 financial results on Monday, May 6, 2024, after the...
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024 07:05 ET
|
Travere Therapeutics, Inc.
Travere and CSL Vifor announce EC approval of FILSPARI (sparsentan) for treatment of IgAN, 1st non-immunosuppressive treatment for IgAN approved in Europe
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
April 04, 2024 16:30 ET
|
Travere Therapeutics, Inc.
Travere to present abstracts at SIMD and GMDI highlighting research investigating pegtibatinase as the first potential disease-modifying therapy for HCU
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
April 03, 2024 16:30 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics to present abstracts at World Congress of Nephrology and American Nephrology Nurses Association on Rare Kidney Disease
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2024 17:00 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, March 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on March 10, 2024, the Compensation Committee of its Board of Directors granted...